» Authors » Y Shirota

Y Shirota

Explore the profile of Y Shirota including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 31
Citations 636
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, et al.
Br J Cancer . 2004 Sep; 91(7):1245-50. PMID: 15354215
The predictive values of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) gene expressions were retrospectively evaluated in patients with gastric cancer treated by a regimen containing S-1. The study population...
12.
Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, et al.
Br J Cancer . 2003 Oct; 89(8):1486-92. PMID: 14562021
Activation of 5-fluorouracil into its nucleotides requires phosphorylation by three pathways involving orotate phosphoribosyl-transferase (OPRT), uridine phosphorylase (UP), or thymidine phosphorylase (TP). In this study, we investigated the association between...
13.
Yamada H, Ichikawa W, Uetake H, Shirota Y, Nihei Z, Sugihara K, et al.
Clin Colorectal Cancer . 2002 Nov; 1(3):169-73; discussion 174. PMID: 12450430
Thymidylate synthase (TS) expression has been identified as an important predictor of response to 5-fluorouracil (5-FU). However, there is relatively little information on the heterogeneity of TS mRNA expression between...
14.
Shirota Y, Stoehlmacher J, Brabender J, Xiong Y, Uetake H, Danenberg K, et al.
J Clin Oncol . 2001 Dec; 19(23):4298-304. PMID: 11731512
Purpose: To test the hypotheses of whether the relative mRNA expression of the thymidylate synthase (TS) gene and the excision cross-complementing (ERCC1) gene are associated with response to and survival...
15.
Yamada H, Nihei Z, Yamashita T, Shirota Y, Ichikawa W, Sugihara K
Eur J Surg . 2001 Apr; 167(3):199-203. PMID: 11316405
Objective: To find out if it is feasible to extend the indication for local resection of submucosal gastric cancer without increasing the risk of lymph node metastases. Design: Retrospective study....
16.
Shirota Y, Kaneko S, Honda M, Kawai H, Kobayashi K
Hepatology . 2001 Apr; 33(4):832-40. PMID: 11283847
Genes expressed in hepatocellular carcinoma (HCC) were analyzed using cDNA microarrays to clarify gene abnormalities in HCC. mRNA was extracted from cancerous and noncancerous tissues of 10 patients with HCC,...
17.
Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K
Gastroenterology . 2001 Mar; 120(4):955-66. PMID: 11231949
Background & Aims: Complementary DNA (cDNA) microarray technology allows simultaneous expression analysis of hundreds to thousands of genes. We applied the cDNA microarray technique to clarify gene expression profiles in...
18.
Qin W, Yamashita T, Shirota Y, Lin Y, Wei W, Murakami S
Hepatology . 2001 Mar; 33(3):728-37. PMID: 11230755
The hepatitis C virus (HCV) nonstructural protein 5B (NS5B) is an RNA-dependent RNA polymerase (RdRP), a central catalytic enzyme for HCV replication. To further understand the structure and functions of...
19.
Kawai H, Kaneko S, Honda M, Shirota Y, Kobayashi K
Hepatology . 2001 Mar; 33(3):676-91. PMID: 11230749
Liver carcinogenesis is a multistep process involving various genetic alterations. cDNA microarray containing 1,080 elements (930 unique genes) was used to comprehensively analyze the genetic alterations in hepatoma cell lines,...
20.
Ichikawa W, Nihei Z, Uetake H, Yamada H, Shirota Y, Sugihara K
Oncology (Williston Park) . 2000 Dec; 14(10 Suppl 9):41-3. PMID: 11098491
In the United States and Europe, the combination of oral UFT plus leucovorin has been reported to produce objective responses and survival rates similar to those achieved with standard intravenous...